/
Psychiatry
Social Anxiety Disorder (SAD)
2
Pipeline Programs↗
4
Active Trials↗
5
Companies Involved↗
Social Anxiety Disorder (SAD) is an early-stage landscape with 2 programs across 5 companies. The most active players are Vanda Pharmaceuticals, Newleos Therapeutics, Inc.. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 31
Approved
No programs
Analysis
Trial Status
7
clinical trials
Recruiting3 · 43%
Completed3 · 43%
Active, not recruiting1 · 14%
Clinical Trials
Trial Activity
7 trials
Caplyta® in the Treatment of Social Anxiety Disorder: A Double-Blind Study
Recruiting·—·Approved·NCT07799493·40 enrolled
The Objective is to Examine the Effectiveness of Ai Integrated Proactive Thought Control for Social Anxiety Disorder and Compare Its Effectiveness With Active Control Group and Cognitive Behavioral Therapy. Participants With SAD Will be Recruited From Educational Setting, Will Get 8 Therapy Sessions.
Completed·—·Preclinical·NCT07810348·75 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)